© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Posted 7th March 2016

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health

Avant Diagnostics, Inc, a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acqu

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Image

Avant Diagnostics, Inc., a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated, adding key CLIA laboratory and intellectual property capabilities to Avant’s previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the “Transactions”).

THI currently generates over $1.5M in services revenue from some of the world’s leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination today at 4:30 PM ET. To access the conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.

Under the terms of the letter of intent, Avant shall issue to THI 25 million shares of its common stock upon the closing. Amarantus BioScience has provided a convertible note of $400,000 to THI to facilitate the transaction that will be assumed by Avant upon closing of the transactions. As previously disclosed, Avant plans to issue 80 million shares of its common stock to Amarantus Biosciences upon completion of its merger with Amarantus Diagnostics. The Transactions are expected to close in the first half of 2016, and are subject to customary closing conditions.

Gerald E. Commissiong, President & CEO of Amarantus said:

“THI is a leader in the area of signal transduction biology, where they have been able to attract an A-list of pharmaceutical customers collaborating with the company to evaluate the therapeutic benefit and potential of their drug candidates using THI’s proprietary assays.

“In addition, THI has a CLIA lab where Amarantus’ Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company’s suite of high-value, proprietary diagnostics in the areas of oncology and neurology. THI’s sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer’s disease. We could not have picked a better partner to bring Avant and Amarantus’ Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market.”

Gregg Linn, President & CEO of Avant Diagnostics added:

“Key to the business case for the merged company is THI’s impressive pharma services revenue base and sales channel in the area of cell signaling biology. In addition to this, THI’s CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world’s top pharmaceutical companies. THI’s laboratory meets the highest quality standards under CLIA/CAP which should give both our pharmaceutical and commercial customers great confidence in the information generated in THI’s laboratory.”

THI’s core business is centred on providing pharmaceutical and biotechnical companies access to its technology for quantitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform. THI is experienced in running CAP-accredited assays in its CLIA laboratory for predicting response to therapies in difficult to treat cancers.  THI believes that, while genomic approaches may identify potential activating mutations in diseased tissues, measuring the actual activation status of the protein drug targets and the signal transduction pathways that they regulate, provides physicians with much-needed evidence that a particular therapeutic strategy can provide benefits to the patient.  THI has launched tests, TheraLink® Assays, for guiding therapeutic decisions in breast and colorectal cancer. The post-merger Avant Diagnostics will further build on its recognized scientific expertise in the area of cell cycle biology to increase its pharma services revenues and provide therapy guiding diagnostics in difficult to treat conditions.

Glenn Hoke, PhD, Chief Executive Officer of THI added:

“After an extensive evaluation of the diagnostics market, we believe that we have found the best potential partners in Avant and Amarantus. It is clear that we will be expanding our CLIA offerings with much needed tests such as OvaDx in cancer and MSPrecise in neurology, while also providing significant additional pharma services business development opportunities with the LymPro Test. With platforms in microarray proteomics, ELISA, flow cytometry and ‘next-gen’ sequencing, the combined company’s capabilities will allow it to add cross-platform diagnostics as we grow into the future.”

 

 

Categories: Innovation, M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
Boxer Capital, LLC
Finance
26/02/2019Boxer Capital, LLC

Boxer Capital, LLC invents and invests in biotechnology companies that aim to drastically improve medicine. To celebrate the firm’s success in this year’s Hedge Fund Awards we profile it to find out more and explore the secrets behind its success.

Read Full PostRead - Eye Icon
Most Innovative Firm in Hungary
Legal
05/05/2016Most Innovative Firm in Hungary

SBGK has been a significant actor in the Hungarian legal professional market since the 1970’s. It stands out with the thorough knowledge of the intellectual property law practice area.

Read Full PostRead - Eye Icon
Crafting Tailored Messages: How Customization Elevates Campaign Outcomes
News
22/09/2023Crafting Tailored Messages: How Customization Elevates Campaign Outcomes

In the bustling arena of modern marketing, every brand is in a race to capture the audience’s attention. Amidst this noise, how does one make their message resonate with the audience? The key lies in customization. By embracing personalized marketing, br

Read Full PostRead - Eye Icon
4 Tech Pitfalls to Avoid When Launching a Startup
News
31/01/20224 Tech Pitfalls to Avoid When Launching a Startup

Starting a business can be an effective way to boost your finances. It allows you to be innovative by thinking of marketing strategies to promote your business and succeed financially. That’s why you see most young professionals turn to entrepreneurship inst

Read Full PostRead - Eye Icon
GDPR post Brexit: How will this impact hosting and cloud providers?
Legal
21/03/2019GDPR post Brexit: How will this impact hosting and cloud providers?

The UK needed to upgrade its data privacy laws and bring it in line with the rest of the world. The main reason for the GDPR was to assist in harmonising the data privacy laws across Europe, setting a standard that the nations could adhere to.

Read Full PostRead - Eye Icon
Need to Address Multiple Professionals in an Email? Here’s How You Do It
News
20/11/2023Need to Address Multiple Professionals in an Email? Here’s How You Do It

If you ever find yourself in the position of needing to email multiple business associates, it’s essential to know how to address them professionally and respectfully. After all, these are busy professionals. The way you address them in your email can ma

Read Full PostRead - Eye Icon
AMF’s Acquisition of Ownership in Property Portfolio in Helsinki
M&A
03/06/2015AMF’s Acquisition of Ownership in Property Portfolio in Helsinki

AMF's Acquisition of Ownership in Property Portfolio in Helsinki

Read Full PostRead - Eye Icon
The Power of Now: Unleashing Success through Direct Response Marketing
News
06/08/2024The Power of Now: Unleashing Success through Direct Response Marketing

When instant gratification became the order of the day, direct response marketing emerged as one of the most heavy-duty strategies businesses can adopt. It entails immediate action on the consumers’ part and thus has the possibility of enhanced engagemen

Read Full PostRead - Eye Icon
BTCGaw is Now Buying Bitcoins With 11% More Than Blockchain Official Rate
Finance
09/04/2015BTCGaw is Now Buying Bitcoins With 11% More Than Blockchain Official Rate

BTCGaw INC. has announced yesterday its latest offer for Bitcoin sellers: a conversion rate with an 11% increase compared to Blockchain's official rate.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow